Public trial registry of the CCC-Munich

Trial ACT-2

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
ACT-2
World
Full title
:

Alemtuzumab and Chemotherapy in T-cell-Lymphoma: CHOP-14 with or without the monoclonal anti-CD52 antibody Alemtuzumab in Elderly patients

World
EudraCT number
:
World
Responsible organization
:
Medizinische Klinik III, Telefon: 089440072551 Lmu
Indications
Classification Code Description
ICD-10-GM C84.- Reifzellige T/NK-Zell-Lymphome
Trial design
World
Trial type
:
Interventional
World
Phase
:
III
Status
World
Status
:
Recruitment finished
Votes
World
Institutional review board - vote
:
Unknown
Initiiation & lock
World
Date of lock (planned / actual)
:
Unknown / Unknown
Participants The lead of this trial has not explicitely given their approval for publishing the contact information of the principal investigators or specific contact persons.